Sugimoto Toshitsugu
Internal Medicine 1, Shimane University Faculty of Medicine.
Clin Calcium. 2011 Jan;21(1):46-51.
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) which blocks its binding to RANK, inhibiting the development and activity of osteoclasts, followed by suppression of bone resorption. Denosumb given subcutaneously twice yearly for 3 years was associated with a reduction in the risk of vertebral, nonvertebral and hip fractures but not with serious adverse events in women with osteoporosis. New horizon would be brought about by Denosumab, new molecular targeting pharmaceutics in the treatment of osteoporosis as well as rheumatoid arthritis and metastatic bone diseases.
地诺单抗是一种针对核因子κB受体活化因子配体（RANKL）的全人单克隆抗体，它可阻断RANKL与RANK的结合，抑制破骨细胞的发育和活性，进而抑制骨吸收。在患有骨质疏松症的女性中，每年皮下注射两次地诺单抗，持续3年，可降低椎体、非椎体和髋部骨折的风险，但不会引发严重不良事件。地诺单抗将为骨质疏松症以及类风湿性关节炎和转移性骨病的治疗带来新的分子靶向药物这一全新视野。
